Evidence map›Paper›PMID 29057058›Full record

ArticleACS medicinal chemistry letters2017

Addressing the Metabolic Stability of Antituberculars through Machine Learning.

Thomas P Stratton, Alexander L Perryman, Catherine Vilchèze, Riccardo Russo, Shao-Gang Li, Jimmy S Patel, Eric Singleton, Sean Ekins, Nancy Connell, William R Jacobs and 1 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Generation of new inhibitors of selected cytochrome P450 subtypes-Computational and structural biotechnology journal · 2022
    Article
  3. Article
  4. Article
  5. Random Forest Model Prediction of Compound Oral Exposure in the Mouse.ACS pharmacology & translational science · 2021
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thomas P StrattonDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
Alexander L PerrymanDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
Catherine VilchèzeHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, United States.
Riccardo RussoDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
Shao-Gang LiDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
Jimmy S PatelDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
Eric SingletonDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
Sean EkinsCollaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, California 94010, United States.
Nancy ConnellDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.
William R JacobsHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, United States.
Joel S FreundlichDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey 07103, United States.

Funding

Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DARTOIS, VERONIQUE · 2014 to 2018
$26.9M
Validation and Application of a Model for Human-like TB Latency in RabbitsU19AI111276 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, ALLAND, DAVID · 2014 to 2020
$23.3M
Molecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR01AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 2022
$7.1M
Biocomputation across distributed private datasets to enhance drug discoveryR44TR000942 · NCATS · COLLABORATIVE DRUG DISCOVERY, INC. · PI BUNIN, BARRY A · 2013 to 2018
$2.9M
NCATS NIH HHS R44 TR000942NIAID NIH HHS R01 AI026170NIAID NIH HHS R37 AI026170NIAID NIH HHS U19 AI109713NIAID NIH HHS U19 AI111276
6 · The paper itself

Abstract

We present the first prospective application of our mouse liver microsomal (MLM) stability Bayesian model. CD117, an antitubercular thienopyrimidine tool compound that suffers from metabolic instability (MLM

Indexed as

antitubercularBayesianchemical tool optimizationcomputer-aided analogue designmachine learningmouse liver microsomal stability

Identifiers

PMID29057058
PMCPMC5642018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.